Targeted pharmacologic immunomodulation for inborn errors of immunity

Area of Science:

• Immunology
• Genetics
• Molecular Biology

Background:

• Inborn errors of immunity (IEI) encompass over 400 single-gene disorders.
• Manifestations include susceptibility to infection, autoimmunity, autoinflammation, hypersensitivity, and cancer predisposition.
• Current treatments like immunoglobulin replacement and immunosuppression offer symptomatic relief but limited impact on morbidity/mortality, with hematopoietic stem cell transplantation not always an option.

Purpose of the Study:

• To review monogenic disorders affecting leukocyte migration, immune synapse formation, and immune cell signal transduction.
• To highlight the therapeutic potential of off-label small molecules and biologics.
• To discuss mechanistically targeted treatments for altered disease pathophysiology in IEI.

Main Methods:

• Literature review of monogenic disorders affecting key immune functions.
• Analysis of current therapeutic strategies for inborn errors of immunity.
• Exploration of emerging targeted therapies, including small molecules and biologics.

Main Results:

• Identification of specific monogenic defects in leukocyte migration, immune synapse formation, and signal transduction pathways.
• Evidence for the efficacy of off-label small molecules and biologics in addressing underlying pathophysiology.
• Demonstration of potential for improved disease management beyond conventional therapies.

Conclusions:

• Targeted therapies, including small molecules and biologics, offer promising new avenues for managing inborn errors of immunity.
• Mechanistic understanding of specific IEI allows for tailored therapeutic interventions.
• Further research into targeted treatments can significantly alter disease course and improve patient outcomes.